<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697006</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 1.1 Version 1.0</org_study_id>
    <nct_id>NCT02697006</nct_id>
  </id_info>
  <brief_title>Synchronized Cardiac Assist for Cardiogenic Shock</brief_title>
  <official_title>Synchronized Cardiac Assist for Cardiogenic Shock. The SynCor Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenios AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAXIS Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect prospective safety and performance information for&#xD;
      the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung&#xD;
      failure or in high risk percutaneous intervention procedures in catheterization lab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 16, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of device and procedure related serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Acute safety defined as rates of device and procedure related serious adverse events up to 30 days post-intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>24 hours</time_frame>
    <description>Technical success (defined as the ability to successfully deliver the i-COR® SYNCHRONIZED CARDIAC ASSIST device without serious adverse events).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device performance success</measure>
    <time_frame>7 days</time_frame>
    <description>Device performance success (defined as the ability to establish synchronized pulsatile cardiac assist, enhance cardiac function and improve tissue oxygenation) assessed immediately post-procedure (acute) and serially as the device remains in place and provides cardiac support over time in each patient.</description>
  </primary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Shock, Cardiogenic</condition>
  <condition>High Risk Percutaneous Coronary Interventions</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i-cor Synchronized Cardiac Assist Device</intervention_name>
    <description>The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiogenic shock or in high risk percutaneous intervention procedures in the&#xD;
        cardiac catheterization lab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients in cardiogenic shock in the setting of acute myocardial infarction&#xD;
&#xD;
        or&#xD;
&#xD;
        Patients undergoing high risk coronary revascularization procedures (e.g., multi-vessel&#xD;
        disease, left main, or last patent conduit interventions) in the catheterization lab.&#xD;
&#xD;
        Cardiogenic shock is defined as&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mmHg for at least 30 min or&#xD;
&#xD;
          -  Inotropes are needed to maintain blood pressure &gt; 90 mmHg or&#xD;
&#xD;
          -  Clinical signs of heart insufficiency with pulmonary congestion or&#xD;
&#xD;
          -  Signs of end organ hypoperfusion with at least one of the following criteria:&#xD;
&#xD;
          -  Altered mental status&#xD;
&#xD;
          -  cold, damp skin or extremities&#xD;
&#xD;
          -  oliguria (≤ 30 mL/h)&#xD;
&#xD;
          -  serum lactate &gt; 2.0 mmol/L&#xD;
&#xD;
        Written consent of the patient or the legal caregiver&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 85 years&#xD;
&#xD;
          -  Cardiac arrest out of hospital with return of spontaneous circulation (ROSC) &gt; 10 min&#xD;
&#xD;
          -  Coma with fixed pupils not induced by drugs;&#xD;
&#xD;
          -  Mechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle&#xD;
             rupture)&#xD;
&#xD;
          -  Non-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)&#xD;
&#xD;
          -  Fever (Body temperature &gt; 38.0 °C) or other evidence of sepsis&#xD;
&#xD;
          -  Onset of cardiogenic shock &gt; 6 h before enrollment;&#xD;
&#xD;
          -  Lactate &gt; 22 mmol/L;&#xD;
&#xD;
          -  Massive pulmonary embolism;&#xD;
&#xD;
          -  Severe peripheral arterial occlusive disease precluding insertion of femoral arterial&#xD;
             or venous catheters&#xD;
&#xD;
          -  Previous known aortic regurgitation greater than grade II&#xD;
&#xD;
          -  Contra-indications for anticoagulation&#xD;
&#xD;
          -  Severe hemolysis of any cause&#xD;
&#xD;
          -  Patient is participating in an investigational drug or device study trial that has not&#xD;
             reached the primary endpoint or that interferes with the current study endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Liebetrau, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik, Cardiology, Bad Nauheim, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hesse</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 17, 2021</submitted>
    <returned>April 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

